CUSP Wealth
Personalised portfoliosIslamic investingPricing and feesAbout usBlogHelp centre

Healthcare

Companies operating in healthcare, pharmaceuticals, and medical innovation.

0 items
Valuation
Price
TXG
10X Genomics Inc
TXG
44
$10.07B
-
$80.89
4.86%
FDMT
4D Molecular Therapeutics Inc
FDMT
33
$701.60M
-
$13.31
4.80%
SXTP
60 Degrees Pharmaceuticals Inc
SXTP
55
$3.42M
-
$0.96
-0.26%
AARD
Aardvark Therapeutics Inc
AARD
33
$103.08M
-
$4.72
0.21%
ABT
Abbott Laboratories
ABT
44
$170.43B
0.64%
$99.59
1.12%
ABBV
AbbVie Inc
ABBV
22
$481.40B
0.64%
$276.39
1.46%
ABCL
Abcellera Biologics Inc
ABCL
33
$3.90B
-
$12.60
4.32%
ABEO
Abeona Therapeutics Inc
ABEO
50
$283.63M
-
$4.95
-0.40%
ABVX
Abivax SA
ABVX
33
$7.71B
-
$88.33
-1.07%
ABSI
Absci Corp
ABSI
27
$1.53B
-
$10.15
13.65%
ABVC
ABVC Biopharma Inc
ABVC
16
$26.16M
-
$1.00
2.04%
ACHC
Acadia Healthcare Company Inc
ACHC
44
$2.65B
-
$29.26
2.74%
ACAD
ACADIA Pharmaceuticals Inc
ACAD
94
$3.37B
-
$19.77
0.97%
ARAY
Accuray Inc
ARAY
33
$28.83M
-
$0.22
-4.72%
ACHV
Achieve Life Sciences Inc
ACHV
22
$739.87M
-
$7.40
2.92%
ACIU
AC Immune SA
ACIU
11
$312.26M
-
$2.50
-1.57%
ACON
Aclarion Inc
ACON
38
$6.66M
-
$2.34
0.00%
ACRS
Aclaris Therapeutics Inc
ACRS
27
$557.88M
-
$3.82
0.79%
ACRV
Acrivon Therapeutics Inc
ACRV
33
$80.14M
-
$1.88
0.53%
ATNM
Actinium Pharmaceuticals Inc
ATNM
66
$33.96M
-
$1.07
-0.93%
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

CUSP Wealth

Have any questions or just want to keep in touch?

Follow us on LinkedInChat on WhatsAppsupport@cuspwealth.compartnerships@cuspwealth.com

*T&Cs apply

Fees SchedulePrivacy & Cookies PolicyTerms & ConditionsPromo Code T&Cs

Cusp Wealth Ltd is authorised and regulated by the Dubai Financial Services Authority (DFSA). The Firm holds a Category 4 licence to serve Retail Clients under licence number 10863 (reference number F011420) and is authorised to advise on financial products and arrange deals in investments. Any information presented here is of a general nature and does not take into account your personal circumstances or financial objectives. All materials used in these communications are for marketing purposes of the Cusp Wealth Application; none are meant to offer to sell, a solicitation of an offer to buy, or a recommendation of any security or other financial instrument. They are not intended to provide investment, other financial, legal, tax, or other advice. Investments involve market volatility, possible capital loss, liquidity limits, and regulatory changes. Past performance of financial products is not a reliable indicator of future results. The value of investments can go down as well as up, and you may lose all or part of your capital. No content from Cusp Wealth should be understood as guaranteeing returns, offering risk-free investments, or promising wealth outcomes. This material is intended for DFSA-defined Retail and/or Professional Clients, and our services are not offered outside the DIFC. If you are unsure of your classification or eligibility, please contact us at support@cuspwealth.com. For interested persons, certain products and services are structured according to Islamic principles and approved under our DFSA-issued Islamic Endorsement.

For more details, please refer to our full disclosure at https://cuspwealth.com/.